A Phase 1, Double-blind (3rd Party Open), Randomized, Placebo-controlled, Dose Escalation Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Repeat Oral Doses Of Pf-06372865 In Healthy Adult Subjects

Trial Profile

A Phase 1, Double-blind (3rd Party Open), Randomized, Placebo-controlled, Dose Escalation Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Repeat Oral Doses Of Pf-06372865 In Healthy Adult Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs PF 6372865 (Primary)
  • Indications Back pain; Epilepsy
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top